Absci Corp (ABSI)

About Absci Corp

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Headquarters: Vancouver, WA · Employees: 140 · Website: https://www.absci.com

Supply-chain relationships for ABSI

• ASTRAZENECA PLC (AZN) — supplier

Frequently asked questions about Absci Corp (ABSI)

What is Absci Corp (ABSI)?

Absci Corp (ABSI) is a publicly traded company in the Services-Commercial Physical & Biological Research sector (Biotechnology), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.

Who are Absci Corp's key suppliers and customers?

Macroplane tracks Absci Corp's (ABSI) supply chain. Key suppliers include ASTRAZENECA PLC (AZN).